180 Life Sciences Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Lloyd Jordan

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.8yrs

Recent management updates

Recent updates

180 Life Sciences to raise $6.5M in direct stock offering

Jul 18

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

Sep 08

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

Feb 17

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

Nov 27

CEO

Lloyd Jordan (55 yo)

less than a year

Tenure

Mr. Lloyd Blair Jordan MBA, LL B, is the Managing Partner of Restructur Advisors. He serves as an Independent Director at Minas Metals Ltd.(formerly known as Lode Metals Corp.) since March 29, 2023. Mr. J...

Board Members

Name	Position	Tenure	Compensation	Ownership
Lawrence Steinman	Co-Founder & Director	5.6yrs	US$253.52k	0.25% $ 5.7k
Lloyd Jordan	Interim CEO & Director	less than a year	no data	no data
Jagdeep Nanchahal	Co-Founder & Chairman of Clinical Advisory Board	no data	no data	no data
Omar Jimenez	CFO & Director	less than a year	no data	no data
Kevin Tracey	Member of Scientific Advisory Board	2.8yrs	no data	no data
Chas Bountra	Member of Scientific Advisory Board	2.8yrs	no data	no data
Ryan Smith	Independent Director	less than a year	no data	no data
Irene Tracey	Member of Scientific Advisory Board	2.8yrs	no data	no data
Sallie Lamb	Member of Scientific Advisory Board	2.8yrs	no data	no data
Jay Goodman	Independent Director	less than a year	no data	no data

2.8yrs

Average Tenure

55yo

Average Age

Experienced Board: ATNF's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

180 Life Sciences Management

Management criteria checks 0/4

Key information

Recent management updates

180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024

180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees

180 Life Sciences Corp. Announces Chief Financial Officer Changes

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Recent updates

180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024

180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees

180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule

180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024

180 Life Sciences Corp. Announces Chief Financial Officer Changes

180 Life Sciences Corp. Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. Provides Non-Compliance Update

180 Life Sciences Corp. Provides Non-Compliance Update

New major risk - Financial position

180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A)

180 Life Sciences Receives a Letter from Nasdaq

High number of new directors

180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency

180 Life Sciences Receives Non-Compliance Notice From Nasdaq

180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq

New minor risk - Share price stability

180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake

180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment

180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

No longer forecast to breakeven

Price target decreased to US$4.00

High number of new and inexperienced directors

180 Life Sciences Receives Non-Compliance Letter from Nasdaq

180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million.

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Price target decreased to US$5.00

High number of new and inexperienced directors

180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022

180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion

180 Life Sciences Corp. Forms Scientific Advisory Board

Lead Independent Director recently bought US$103k worth of stock

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences Corp. announced that it has received $15 million in funding

180 Life Sciences Corp. announced that it expects to receive $15 million in funding

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. announced delayed annual 10-K filing

180 Life Sciences Receives Extension Until June 30, 2021 to Regain Compliance from Nasdaq

180 Life Sciences Corp. announced that it expects to receive $11.6662 million in funding